J.P. Morgan

January43rd Annual14,Healthcare2025 Investment Conference

Olivier Loeillot

President and Chief Executive Officer

January 14, 2025

Who is Repligen?

3

Repligen Snapshot: Innovation Leader in Bioprocessing

  • Supporting Pharma and CDMO's with a broad and differentiated portfolio of hardware & consumables used in their biological drug production
  • Innovation engine … disrupting norms with fast-to-market products that enable yield gains and cost efficiencies
  • Global manufacturing presence with

security of supply

>1,700

employees

  • ~65% clinical, 35% commercial
  • Revenue majority mAb-based (~80%); strong and growing presence in new modalities (~20%)

Performing Above Market

  • 14 disruptive product launches … organic
    R&D and 14 acquisitions since 2014
  • 19% 5-year revenue CAGR

$630 - 639M

Analytics +2x

Proteins steady

Chrom +2x

$270M

Filtration +3x

2019 2024e

We are 10 Years "Young" … And Fit for Growth!

4

2024 Business Highlights

2-3%

~80%

Revenue Growth

2024e Revenue from Highly

ex-COVID

Differentiated Products

Filtration, Chrom &

Examples:

Analytics 6-7%

XCell® ATF

New Modalities up 10%

OPUS® Pre-Packed Columns

RPM-enabled RS TFF

50%+ probability funnel

Launched 3 key new

up >15% at YE24

products in 2024

~ +100 bps

M&A

68%

Gross Margin

Executing with Strict

Reduction in Scope 2

Expansion

Criteria

Emissions

Net price realization

Tantti acquisition …

88% global electricity

base matrix enables

usage powered by

Strong execution of

full resin capabilities

100% renewable

manufacturing RPS

Operating expense

Successful integration

3rd Sustainability

management

of Metenova

report published

*Sustainability Data is

for year 2023

Solid performance in a challenging year

5

Strong End Markets with Positive Trends Entering 2025

mAb-based

Therapeutics ~$250B

Most mature,

largest, steady Market 2024e

~$15B

Biosimilar mAbs

Rapidly expanding

~$15B

subset

New

Modalities

~$16B

Youngest,

fastest growing

8-10% Projected CAGR

184 US FDA approvals ~2K Ph 1-3 clinical pipeline

>20% Projected CAGR

43 US FDA approvals >150 Ph 1-3 clinical pipeline

>30% Projected CAGR

29 US FDA approvals

>3K in development pipeline

Market Trends

  • Biopharma market growing HSD with aging population
  • Majority of R&D pipeline in new modalities
  • Development and manufacturing costs under more scrutiny
  • Local governments pushing for localization
  • U.S. biggest region for sales, APAC for trials
  • Generative AI already playing a key role in drug discovery and beyond

US FDA approval data as of Jan. 6, 2025 Projected CAGR is for 4-year period from proprietary research reports

6

Broad Portfolio Across the Bioproduction Workflow; Addressing Pain Points

Broad Portfolio Across the Bioproduction Workflow; Addressing Pain Points

How are we Different?

Our approach to winning through differentiation

9

Repligen's Value Creation Equation

StrategyCapabilities

Results: 2014 to 2024e

  • 100% Bioprocessing including Analytics
  • Disruptive technology launches

to generate productivity gains

  • Extensive portfolio across mAbs and new modalities workflows
  • Disciplined M&A with strong return creates differentiation
  • Innovation enabling customer efficiency
  • Our culture … nimble,

collaborative, transparent

  • Commercial & Operations excellence
  • Fit for Growth … talent, expertise, process rigor
  • 10-foldincrease in revenue
  • Adj. EPS $0.24 to $1.54
  • 3-foldincrease in TAM
  • Market cap ~$600M to ~$9B

Confidence in our ability to grow above market and expand margin over the next 5 years

Adj. EPS 2024e reflects midpoint of guidance provided Nov. 12, 2024

10

Attention: This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Repligen Corporation published this content on January 18, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 18, 2025 at 19:04:01.621.